Author(s): Altieri DC, Altieri DC
Abstract Share this page
Abstract A little over 10 years after its discovery in 1997, the small inhibitor of apoptosis (IAP) protein, survivin, continues to generate intense interest and keen attention from disparate segments of basic and disease-related research. Part of this interest reflects the intricate biology of this multifunctional protein that intersects fundamental networks of cellular homeostasis. Part is because of the role of survivin as a cancer gene, which touches nearly every aspect of the disease, from onset to outcome. And part is due to the potential value of survivin for novel cancer diagnostics and therapeutics, which have already reached the clinic, and with some promise. Grappling with emerging new signaling circuits in survivin biology, and their implications in cancer, will further our understanding of this nodal protein, and open fresh opportunities for translational oncology research.
This article was published in Oncogene
and referenced in Single Cell Biology